Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-369-3p mimic is a synthetic oligonucleotide designed to replicate the function of endogenous miR-369-3p, a microRNA known for post-transcriptional regulation of gene expression. It is commonly used in research settings to restore or enhance miR-369-3p activity in cellular or animal models for mechanistic or therapeutic studies. miR-369-3p mimic operates by base pairing with complementary sequences in target mRNAs, leading to their degradation or translational repression. Studies have shown that miR-369-3p mimic can regulate inflammatory responses (notably in models of inflammatory bowel disease and atherosclerosis), inhibit tumor cell proliferation by downregulating targets like TSPAN13, BRCC3, TCF4, and modulate the NLRP3 inflammasome. There is no evidence it is currently developed for clinical use as a pharmaceutical drug; its application is primarily experimental as an RNA therapeutic or genetic tool[1][2][3][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on miR-369-3p mimic.